Status:
COMPLETED
A Study in Subjects With Perennial Allergic Rhinitis
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Perennial Allergic Rhinitis
Phase:
PHASE2
Brief Summary
The purpose of this study was to determine the efficacy and safety of the study drug compared to placebo for the treatment of subjects with perennial allergic rhinitis.
Eligibility Criteria
Inclusion
- Have a documented history of allergy to perennial allergens and demonstrated sensitivity by the results of prick or intradermal skin testing.
- Have a self-reported history of at least mild, intermittent rhinorrhea and nasal blockage/stuffiness due to allergies.
- Have not started or had a change in immunotherapy regimen.
Exclusion
- Have a physical obstruction in the nose.
- Will likely have an acute increase in severity of allergic rhinitis due to seasonal aeroallergens during the trial.
- Have acute or chronic sinusitis or had previous sinus surgery resulting in a significant change in the sinus or nasal anatomy.
- Have rhinitis medicamentosa or any other acute or chronic condition that could confound evaluations of nasal symptoms.
- Have asthma of sufficient severity to require use of excluded medications.
- Have taken any medications excluded as listed in the protocol.
- Have a clinically significant acute or chronic disease or clinically significant laboratory abnormality.
- Are a current smoker, recent smoker or past smoker as defined in the protocol.
Key Trial Info
Start Date :
December 1 2002
Trial Type :
INTERVENTIONAL
End Date :
April 1 2003
Estimated Enrollment :
630 Patients enrolled
Trial Details
Trial ID
NCT00210015
Start Date
December 1 2002
End Date
April 1 2003
Last Update
January 25 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.